Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2012 1
2013 3
2014 4
2015 2
2016 3
2017 2
2018 1
2019 3
2020 8
2021 7
2022 6
2023 8
2024 14
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023. Front Immunol. 2024. PMID: 38274801 Free PMC article.
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. JAMA Dermatol. 2025 Feb 1;161(2):147-156. doi: 10.1001/jamadermatol.2024.4796. JAMA Dermatol. 2025. PMID: 39602139 Clinical Trial.
Chronische Nierenerkrankung bei Psoriasis: eine Kohortenstudie.
Conti A, Giovannini L, Mandel VD, Odorici G, Lasagni C, Bigi L, Pellacani G, Cappelli G. Conti A, et al. Among authors: lasagni c. J Dtsch Dermatol Ges. 2020 May;18(5):438-446. doi: 10.1111/ddg.14087_g. J Dtsch Dermatol Ges. 2020. PMID: 32413229 German.
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.
Bonifati C, Lembo S, Richetta AG, Romanelli M, Satolli F, Corazza M, Atzori L, Lasagni C, Potenza C, Savoia P, Bardazzi F, Di Lernia VG, Bianchi L, Fabbrocini G, Giofrè C, Zichichi L, Guarneri C, Pallotta S, Fargnoli MC, Loconsole F, Offidani A, Burlando M, Piaserico S, Peris K, Papini M, Carrera CG, Costanzo A, Prignano F, Bongiorno MR, Dapavo P, Stingeni L, Donini M, Micali G, Rongioletti F, Stinco G, Gramiccia T, Cantini G, Argenziano G. Bonifati C, et al. Among authors: lasagni c. J Eur Acad Dermatol Venereol. 2025 Mar;39 Suppl 1:7-14. doi: 10.1111/jdv.20187. Epub 2024 Jun 26. J Eur Acad Dermatol Venereol. 2025. PMID: 38924150
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis).
Megna M, Orsini D, Assorgi C, Balato A, Balestri R, Bianchi L, Brianti P, Brunasso G, Buononato D, Burlando M, Cagni AE, Caldarola G, Cameli N, Campanati A, Campione E, Carrera CG, Carugno A, Chersi K, Costanzo A, Cusano F, D'Amico D, Dal Bello G, Dapavo P, Dattola A, De Simone C, Di Lernia V, Dini V, Errichetti E, Esposito M, Fargnoli MC, Fiorella CS, Foti A, Gaiani FM, Gargiulo L, Gatti A, Gisondi P, Giunta A, Ibba L, Lasagni C, Loconsole F, Maione V, Malagoli P, Marzano AV, Maurelli M, Mercuri SR, Michelerio A, Michelucci A, Morrone P, Mortato E, Narcisi A, Offidani A, Paolino G, Parodi A, Pellacani G, Quaglino P, Richetta AG, Romano F, Sena P, Trevisan G, Uzzauto MT, Venturini M, Potestio L. Megna M, et al. Among authors: lasagni c. Clin Exp Dermatol. 2025 Mar 26;50(4):858-859. doi: 10.1093/ced/llae400. Clin Exp Dermatol. 2025. PMID: 39373543 No abstract available.
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis).
Valenti M, Ibba L, Di Giulio S, Dapavo P, Malagoli P, Marzano AV, Loconsole F, Burlando M, Balato A, Dini V, Megna M, Girolomoni G, Trovato E, Lasagni C, Travaglini M, Guarneri C, Zerbinati N, Ribero S, Gaiani FM, Carrera CG, Cozzani EC, Di Brizzi EV, Michelucci A, Potestio L, Maurelli M, Dragotto M, Mastorino L, Bongiovanni E, Messina F, Sechi A, Moroni R, Costanzo A, Narcisi A. Valenti M, et al. Among authors: lasagni c. Dermatol Ther (Heidelb). 2025 Sep;15(9):2423-2437. doi: 10.1007/s13555-025-01476-1. Epub 2025 Jul 3. Dermatol Ther (Heidelb). 2025. PMID: 40608253 Free PMC article.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495. J Clin Med. 2024. PMID: 38256629 Free PMC article.
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study.
Satolli F, Gerosa S, Burlando M, Cozzani EC, Lasagni C, Manfredini M, Narcisi A, Marzano AV, Carrera CG, Megna M, Cagni A, Esposito M, Fargnoli MC, Di Lernia V, Peccerillo F, Romanelli M, Trovato E, Amerio P, Carugno A, Brunasso G, Rech G, Balestri R, Mastorino L, Quaglino P, Brusasco M, Feliciani C. Satolli F, et al. Among authors: lasagni c. Clin Exp Dermatol. 2025 Aug 22;50(9):1827-1833. doi: 10.1093/ced/llaf184. Clin Exp Dermatol. 2025. PMID: 40521671
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).
Valenti M, Ibba L, Di Giulio S, Gargiulo L, Malagoli P, Balato A, Bardazzi F, Loconsole F, Burlando M, Cagni AE, Cameli N, Carrera CG, Carugno A, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Fargnoli MC, Gaiani FM, Guarneri C, Lasagni C, Licata G, Marzano AV, Megna M, Mercuri SR, Michelucci A, Musumeci ML, Orsini D, Ortega R, Potestio L, Rapparini L, Ribero S, Satolli F, Strippoli D, Trovato E, Venturini M, Zichichi L, Brianti P, Costanzo A, Narcisi A. Valenti M, et al. Among authors: lasagni c. Dermatol Ther (Heidelb). 2025 Jun;15(6):1427-1440. doi: 10.1007/s13555-025-01416-z. Epub 2025 Apr 23. Dermatol Ther (Heidelb). 2025. PMID: 40266488 Free PMC article.
63 results